Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Mar 29;104(7):1238-9.
doi: 10.1038/bjc.2011.52. Epub 2011 Mar 8.

Severe hypertriglyceridaemia during treatment with capecitabine

Case Reports

Severe hypertriglyceridaemia during treatment with capecitabine

L Javot et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical course of triglyceride (▪) and cholesterol (▴) levels in patients, expressed in mmol l−1.

Comment on

References

    1. Brockenbrough JS, Morihara JK, Hawes SE, Stern JE, Rasey JS, Wiens LW, Feng Q, Vesselle H (2009) Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem 57: 1087–1097 - PMC - PubMed
    1. Kurt M, Babaoglu O, Yasar U, Shorbagi A, Guler N (2006) Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 40: 328–331 - PubMed
    1. Michie CO, Sakala M, Rivans I, Strachan MWJ, Clive S (2010) The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 103: 617–621 - PMC - PubMed
    1. Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE (1995) Influence of 5-fluorouracil on serum lipids. Acta Oncol 34: 253–256 - PubMed
    1. Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, Smid K, Honeywell RJ, Ylstra B, Ejik PP, Fukushima M, Peters GJ (2010) Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleotide transporter expression or increased secretory phospholipase A2. Mol Cancer Ther 9: 1047–1057 - PubMed

MeSH terms